FDA Approved: ZYCLARA — Supplemental Application (Bausch Health US, LLC)

View source ↗

Summary

FDA approved a supplemental application for ZYCLARA (imiquimod) to update the labeling with new or expanded indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Genital Warts
• Superficial Basal Cell Carcinoma

Drugs mentioned

• ZYCLARA (Imiquimod)

Snippet

SUPPL AP for ZYCLARA (IMIQUIMOD)